You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國家衛健委:第二代新冠疫苗已完成II期臨牀試驗 國藥集團正研發兩款新冠特效藥
阿思達克 09-13 07:43
據《央視》引述國家衛生健康委科技發展中心主任鄭忠偉表示,內地疫苗研發單位已開展Gamma株和Delta株的滅活疫苗研究,並開展針對不同變異株的廣譜或多價重組蛋白疫苗的研究,開展針對Beta株、Delta株的腺病毒載體疫苗和核酸疫苗的研發工作。 國藥集團中國生物黨委書記朱京津透露,目前公司針對德爾塔和貝塔等變異毒株的疫苗已經制備出來。廣譜重組蛋白二代疫苗也已經研發出來,已經完成I、II期臨牀試驗。(ta/w) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account